Novel treatment options for pediatric HIV infection

Current Opinion in Investigational Drugs

Volumn 9, Issue 2, 2008, Pages 170-175

  Day, E ^a   Buckberry, K ^a   Sharland, M R ^a   Chakraborty, R ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Children; HIV; Pharmacokinetics; Treatment

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR;

CARDIOPULMONARY ARREST; CHILDHOOD DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; FATIGUE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INJECTION SITE REACTION; NAUSEA; PANCYTOPENIA; REVIEW; SIDE EFFECT; STROKE;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; INFANT; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 38849096506     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Taking stock: HIV in children. World Health Organisation, Geneva, Switzerland (2006). http://www.who.int/hiv/toronto2006/Children2_eng.pdf
2. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM: PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med (2004) 5(Suppl 2):61-86. • A succinct summary of current pediatric practice. These guidelines will be revised to reflect the new drugs that have been summarized in this review.
3. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, Butler K, Riordan A, Farrelly L, Masters J, Peckham CS et al: Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ (2003) 327(7422):1019.
4. Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, Novelli V, Riordan A, Dunn D, Walker AS, Gibb DM: Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J (2006) 25(5):420-426.
5. Steele RG, Grauer D: Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research. Clin Child Fam Psychol Rev (2003) 6(1):17-30.
6. Pontali E: Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: What are the issues and what can be done? Paediatr Drugs (2005) 7(3):137-149.
7. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics (1994) 94(6 Pt 1):815-819.
8. King JR, Kimberlin DW, Aldrovandi GM, Acosta EP: Antiretroviral pharmacokinetics in the paediatric population: A review. Clin Pharmacokinet (2002) 41(14):1115-1133.
9. de Béthune M-P, Andries K, Azijn H, Guillemont J, Heeres J, Vingerhoets J, Lewi P, Lee E, Timmerman P, Williams P: TMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profile. Conference on Retroviruses and Opportunistic Infections (2005) 12:Abs 556.
10. Bauman JD, Das K, Baweja M, Clark A Jr, Boyer P, Shatkin A, Lewi P, Hughes S, Arnold E: Structures of HIV-1 reverse transcriptase complexed with NNRTI TMC278: Conformational and positional adaptability overcomes resistance mutations. Conference on Retroviruses and Opportunistic Infections (2007) 14:Abs 88.
11. Pozniak A, Morales-Ramirez J, Mohapi L, Santoscoy M, Chetchotisakd P, Hereygers M, Vanveggel S, Peeters M, Woodfall B, Boven K: 48-Week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients. Conference on Retroviruses and Opportunistic Infections (2007) 14:Abs 144LB.
12. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Béthune MP: TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol (2005) 79(20):12773-12782.
13. Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peeters M, Rinehart A, de Dier K, Baede-Van Dijk P, Parys W, van 't Klooster G: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS (2003) 17(17):2487-2494.
14. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, van 't Klooster G: An open-label assessment of TMC 125 - a new, next generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS (2003) 17(18):49-54. • Important preliminary data on a drug that will have a role in the management of children and adolescents with key NNRTI resistance mutations.
15. Cohen C, Steinhart CR, Ward DJ, Ruane PJ, Vingerhoets J, Peeters M, White A, Baeten B, de Bethune M, Woodfall B: Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. International AIDS Conference (2006) 13:Abs TUPE0061.
16. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Béthune MP, Schiffer CA: Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol (2004) 78(21):12012-12021.
17. Lazzarin A, Queiroz-Telles F, Frank I, Rockstroh J, Walmsley S, De Paepe E, Vangeneugden T, Spinosa-Guzman S, Lefebvre E: TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. International AIDS Conference (2006) 16:Abs TUAB0104.
18. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W et al: Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-Week results of POWER 1. AIDS (2007) 21(4):395-402. • A well-designed clinical trial presenting initial encouraging data on the effects of darunavir in treatment-experienced adults.
19. Grinsztejn B, Arasteh K, Clotet B, Cunha CA, Goffard JC, Guzman SS, Hill A, Molina JM, Tanski C, Walgraeve H: TMC114/r is well tolerated in 3-class-experienced patients: Week 24 primary analysis of POWER 1 (TMC114-C213). International AIDS Society Conference (2005) 3:Abs WePeLB6.201.
20. Berger DS, Bellos N, Farthing C, Stryker R, Colson A, Pierone G, Lefebvre E, Cefalone M, Koester A, Van Baelen K, De Pauw M: TMC114/r in 3-class-experienced patients: 24-Wk primary safety analysis of the POWER 2 study (C202). ICAAC (2005) 45:Abs H-1094.
21. Darunavir [package insert]. Tibotec BVBA, East Bridgewater, NJ, USA (2006):July 30.
22. De Meyer S, Hill A, De Baere I, Rimsky L, Azijn H, Van Baelen B, De Paepe E, Vangeneugden T, Lefebvre E, De Béthune MP: Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: Preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 157.
23. Rutstein R, Samson P, Kiser J, Fletcher C, Graham B, Schnittman S, Smith M, Mofenson L, Fenton T, Aldrovandi G, PACTG 1020A Study Team: The PACTG 1020A protocol: Atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents. Conference on Retroviruses and Opportunistic Infections (2007) 14:Abs 715.
24. + pediatric patients administered tipranavir/ritonavir: BI 1182.14 and PACTG 1051 study team. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 687
25. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J et al: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 348(22):2175- 2185. •• This paper and reference [26••] present data from TORO 1 and TORO 2, well designed clinical trials examining the effects of a new class of ART among individuals with drug-resistant HIV infection. Difficulties with side effects and administration have made this drug a less attractive option for treatment in children.
26. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L et al: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 348(22):2186-2195. •• This paper and reference [25••] present data from TORO 1 and TORO 2, well designed clinical trials examining the effects of a new class of ART among individuals with drug-resistant HIV infection. Difficulties with side effects and administration have made this drug a less attractive option for treatment in children.
27. Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ et al: Durable efficacy of enfuvirtide over 48 weeks in heavily treatment- experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 40(4):404-412.
28. Lazzarin A, Queiroz-Telles F, Frank I, Rockstroh J, Walmsley S, De Paepe E, Vangeneugden T, Spinosa-Guzman S, Lefebvre E: TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. International AIDS Conference (2006) 16:Abs TUAB0104.
29. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H: Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet (2006) 368(9534):466-475. • An informative analysis examining the effects of a relatively new PI in PI-experienced adults with drug-resistant HIV-1. Boosted tipranavir has proved useful for adolescents with key PI mutations.
30. Church JA, Cunningham C, Hughes M, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Purdue L, Hawkins E, Sista P: Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J (2002) 21(7):653-659.
31. Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, Cotler S, Delora P: Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J (2004) 23(12):1137-1141.
32. Zhang X, Lin T, Bertasso A, Evans C, Dorr A, Kolis SJ, Salgo M, Patel I: Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. J Clin Pharmacol (2007) 47(4):510-517.
33. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, Cunningham CK: Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J (2004) 23(8):713-718.
34. Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K et al: Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 40(4):413-421.
35. Melby T, Sista P, DeMasi R, Kirkland T, Roberts N, Salgo M, Heilek-Snyder G, Cammack N, Matthews TJ, Greenberg ML: Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses (2006) 22(5):375-385.
36. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, Kuritzkes DR: Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J Acquir Immune Defic Syndr (2006) 43(1):60-64.
37. Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, Kazatchkine MD, Bélec L: Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr (2007) 44(1):1-5.
38. Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, Patel IH: Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther (2004) 75(6):558-568.
39. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N: Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet (2005) 44(2):175-186.
40. Lalezari J, Goodrich J, DeJesus E, Lampiris H, Gulick R, Saag M, Ridgway C, McHale M, van der Ryst E, Mayer H: Efficacy and safety of maraviroc plus optimized background therapy in viraemic ART-experienced patients infected with CCR5-tropic HIV-1: 24-Week results of a phase 2b/3 study in the US and Canada. Conference on Retroviruses and Opportunistic Infections (2007) 14:Abs 104bLB.
41. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol (2006) 80(10):4909-4920.
42. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L et al: Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 43(5):509-515.
43. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet (2007) 369(9569):1261-1269. • One of the few completed reports on this new class of drug which will influence our practice over the forthcoming years.
44. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, Chen J, Isaacs R, Teppler H, Nguyen B: Results from BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Conference on Retroviruses and Opportunistic Infections (2007) 14:Abs 105aLB.
45. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, Zhao J, Isaacs R, Nguyen B, Teppler H: Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Conference on Retroviruses and Opportunistic Infections (2007) 14:Abs 105bLB.
46. A phase I/II, multicenter, open-label, noncomparative study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) group to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of raltegravir (MK-0518) in HIV-1 infected children and adolescents PACTG 1066. General Clinical Research Center, Stony Brook, NY, USA (2007). http://indigo.gcrc.sunysb.edu/Factsheet.aspx?ProtocolNumber=07-531-36
47. Petry AS, Wenning LA, Laethem M, Smet MDE, Kost JT, Merschman S, Storhmaier K, Ramael S, Lasseter K, Stone JA, Gottesdiener KM et al: Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects. ICAAC (2006) 46:Abs A-376.
48. Kassahun K, McIntosh I, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA: Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. ICAAC (2006) 46:Abs A-372.
49. Iwamoto M, Wenning LA, Petry AS, Laethem M, Desmet M, Kost JT, Merschman S, Mangin E, Azrolan N, Greenberg HE, Haazen W et al: Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518. ICAAC (2006) 46:Abs A-373.
50. Wenning LA, Hanley H, Stone J, Moreau A, Kost JT, Mangin E, Shamp T, Azrolan N, Gottesdiener KM, Wagner JA, Iwamoto M: Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518. ICAAC (2006) 46:Abs A-374.
51. Wenning LA, Friedman E, Kost JT, Merschman S, Lasseter K, Azrolan N, Gottesdiener M, Wagner JA, Stone J, Iwamoto M: Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF). ICAAC (2006) 46:Abs A-375.
52. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P et al: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med (2007) 356(2):135-147.
53. Geretti AM, Smith M, Watson C, Mullen J, Osner N, O'Shea S, Chrystie I, Zuckerman M, Easterbrook P: Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1. AIDS (2002) 16(17):2358-2360.